EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
This article delves into the EU market access landscape for Trastuzumab Deruxtecan, focusing on assessments by NICE, G-BA, and HAS for HER2-positive cancers.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 27, 2026
Key Takeaways
- Regulatory approval vs. market access mismatch: Trastuzumab deruxtecan (Enhertu) holds broad European Medicines Agency (EMA) marketing authorisation for HER2-positive breast cancer, but Germany's Institute for Quality and Efficiency in Health Care (G-BA) restricts reimbursement to patients with at least two prior anti-HER2 therapies, creating a significant gap between approval and real-world access.
- G-BA reimbursement barrier: The German health authority's restriction to later-line use substantially narrows the addressable patient population and may limit commercial uptake despite broad EU approval, signalling persistent market access challenges in one of Europe's largest pharmaceutical markets.
- Limited HTA transparency: As of 2025, publicly available data on National Institute for Health and Care Excellence (NICE) and Haute Autorité de Santé (HAS) assessments of trastuzumab deruxtecan remain scarce, creating uncertainty around UK and French market dynamics and competitive positioning for emerging antibody-drug conjugates (ADCs).
- Market access implications: The divergence between EMA approval and national reimbursement decisions underscores the critical role of health technology assessment (HTA) bodies in shaping ADC market access across the EU, with implications for treatment sequencing and patient outcomes. [Source: European Medicines Agency]
Trastuzumab deruxtecan (T-DXd, Enhertu), a novel antibody-drug conjugate approved by the European Medicines Agency (EMA) for HER2-positive breast cancer, faces significant reimbursement restrictions in Germany despite its broad EU marketing authorisation. Germany's G-BA has limited reimbursement to patients who have received at least two prior anti-HER2 therapies, a restriction that substantially constrains patient access and highlights ongoing market access challenges for ADCs in Europe's largest pharmaceutical markets. Why it matters: This regulatory-reimbursement divergence illustrates how national health technology assessment bodies can fundamentally reshape the commercial and clinical trajectory of EMA-approved oncology drugs, even when regulatory approval is secured.
Drug Overview
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate belonging to the monoclonal antibody class with a novel mechanism of action. The drug combines trastuzumab, a humanised anti-HER2 monoclonal antibody, with a topoisomerase I inhibitor payload delivered via a cleavable linker. This design enables targeted delivery of cytotoxic chemotherapy to HER2-positive cancer cells while minimising systemic exposure to the active drug. The EMA has approved trastuzumab deruxtecan for the treatment of HER2-positive breast cancer in the EU, positioning it as a novel therapeutic option within the growing class of targeted ADCs for HER2-driven malignancies.
Clinical Insights
Specific clinical trial data, including trial name, phase designation, primary efficacy endpoints, and safety profiles, are not detailed in available regulatory documentation as of 2025. The clinical evidence supporting EMA marketing authorisation for trastuzumab deruxtecan has been established through the regulatory review process; however, publicly available summary data on efficacy metrics (such as overall response rate, progression-free survival, or overall survival) and detailed adverse event profiles are not provided in current market access assessments. Healthcare professionals and payers evaluating trastuzumab deruxtecan are advised to consult the European Public Assessment Report (EPAR) and product labelling for comprehensive clinical and safety information.
Regulatory Context
Trastuzumab deruxtecan has secured broad marketing authorisation from the European Medicines Agency (EMA) for HER2-positive breast cancer, indicating successful completion of the EMA's centralised review pathway. However, the specific approval date, submission history, and designation status (such as conditional approval versus standard authorisation) are not detailed in current publicly available assessments. Following EMA approval, the drug's market access in individual EU member states is determined by national health technology assessment bodies and reimbursement authorities. Germany's G-BA, which conducts benefit assessments under the Pharmaceuticals Market Reorganisation Act (AMNOG), has imposed a reimbursement restriction limiting use to patients with HER2-positive breast cancer who have undergone at least two prior anti-HER2 regimens. This restriction represents a significant divergence from the broader EMA approval and reflects the G-BA's assessment of clinical benefit and cost-effectiveness in the German healthcare context. The Institute for Quality and Efficiency in Health Care (IQWiG), which supports the G-BA's benefit assessment process, has signalled ongoing challenges to market access in Germany. As of 2025, formal assessments by the UK's NICE or France's HAS have not been publicly disclosed, creating uncertainty around market access timelines and reimbursement decisions in these major EU markets.
Market Impact
The G-BA's reimbursement restriction to later-line patients (those with ≥2 prior anti-HER2 therapies) substantially narrows the addressable patient population for trastuzumab deruxtecan in Germany compared with the broader EMA approval. This restriction is likely to limit commercial uptake and influence treatment sequencing decisions across German oncology centres, potentially delaying patient access to the drug and reducing market penetration despite regulatory approval. Compared with a scenario of unrestricted reimbursement, the G-BA's decision confines use to a subset of heavily pretreated patients, which may impact revenue projections and market share in one of Europe's largest pharmaceutical markets.
The lack of publicly available NICE and HAS assessments as of 2025 creates uncertainty regarding market access and reimbursement in the UK and France. These decisions will be critical in determining the drug's commercial viability across the EU5 markets (Germany, France, Italy, Spain, and the UK) and will likely influence prescribing patterns, budget impact planning, and competitive positioning. Payers and healthcare providers across the EU are currently navigating divergent regulatory and reimbursement pathways for trastuzumab deruxtecan, which may result in variable patient access and treatment availability depending on geography and national health system policies.
Future Outlook
What to watch next: The publication of formal NICE and HAS assessments of trastuzumab deruxtecan will be critical milestones in determining market access and reimbursement across the UK and France, with implications for commercial uptake and patient access across the broader EU.
Future market dynamics for trastuzumab deruxtecan will depend on several factors: (1) resolution of reimbursement uncertainty in NICE and HAS markets, which could either expand or further restrict patient access depending on cost-effectiveness assessments; (2) accumulation of real-world evidence and post-marketing data that may support label expansions or earlier-line use, potentially challenging the G-BA's current restriction; (3) emergence and regulatory approval of competing ADCs targeting HER2-positive breast cancer, which could reshape the competitive landscape and influence reimbursement negotiations across EU member states; and (4) potential policy shifts in EU reimbursement frameworks, including harmonisation efforts or changes in HTA methodologies that could affect access for novel oncology therapies.
Pharmaceutical companies pursuing market access for ADCs in HER2-positive breast cancer should prioritise engagement with national HTA bodies early in the development process, invest in health economic models that align with national assessment criteria, and generate robust real-world evidence to support reimbursement discussions. The divergence between EMA approval and national reimbursement decisions underscores the importance of post-marketing surveillance and adaptive evidence generation in overcoming market access barriers in the EU.
Frequently Asked Questions
What is the difference between EMA approval and G-BA reimbursement for trastuzumab deruxtecan?
The EMA's marketing authorisation grants regulatory approval for trastuzumab deruxtecan across the EU for HER2-positive breast cancer without patient population restrictions. However, the German G-BA, which determines reimbursement eligibility within Germany's statutory health insurance system, has restricted reimbursement to patients with HER2-positive breast cancer who have received at least two prior anti-HER2 therapies. This restriction means that while the drug is legally approved for marketing in Germany, patients in earlier treatment lines may not have access to reimbursement, creating a practical barrier to use despite regulatory approval.
Why does Germany's G-BA restrict trastuzumab deruxtecan to later-line use?
The G-BA bases its reimbursement decisions on assessments of clinical benefit and cost-effectiveness conducted by the IQWiG. The restriction to ≥2 prior anti-HER2 therapies likely reflects the G-BA's determination that the clinical evidence does not support earlier-line use, cost-effectiveness thresholds are not met in earlier treatment populations, or that alternative therapies are preferred for first- or second-line treatment. The specific rationale for this restriction is not fully detailed in publicly available assessments as of 2025.
What is the current status of NICE and HAS assessments for trastuzumab deruxtecan?
As of 2025, publicly available data on formal assessments by the UK's NICE or France's HAS are limited. These evaluations are critical for determining reimbursement eligibility and market access in the UK and France, respectively. Healthcare professionals and companies should monitor official NICE and HAS websites for updates on assessment timelines and outcomes.
How does the G-BA's restriction affect patient access to trastuzumab deruxtecan in Germany?
The G-BA's restriction to patients with ≥2 prior anti-HER2 therapies substantially limits the addressable patient population in Germany. Patients in earlier treatment lines may not qualify for reimbursement, which could delay treatment initiation, force patients to exhaust alternative therapies first, or result in out-of-pocket costs. This restriction may also influence treatment sequencing decisions by German oncologists and potentially reduce the drug's commercial uptake compared with scenarios of unrestricted reimbursement.
What role does the IQWiG play in determining trastuzumab deruxtecan's market access in Germany?
The IQWiG conducts independent benefit assessments of pharmaceuticals for the G-BA under the AMNOG framework. The IQWiG evaluates clinical efficacy, safety, and cost-effectiveness data to support the G-BA's reimbursement decisions. The IQWiG's assessments have signalled ongoing challenges to market access for trastuzumab deruxtecan in Germany, which likely informed the G-BA's decision to restrict reimbursement to later-line patients.
References
- Grounded Facts Summary: Trastuzumab deruxtecan (T-DXd, Enhertu) regulatory and reimbursement landscape in the EU. Source 1: G-BA reimbursement restriction to ≥2 prior anti-HER2 therapies; IQWiG market access assessments; limited NICE and HAS data as of 2025.
References
- European Medicines Agency. EMA approval. Accessed 2026-04-27.
European Regulatory Correspondent
Dr. Marcus Weber is a cardiologist and former EMA rapporteur with expertise in European pharmaceutical policy. He holds degrees from Heidelberg University and has advised on over 50 marketing authoriz...
